Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.
Key Details
- 1A new analysis reviewed FDA approval and recall databases for all AI/ML devices cleared from 1995 to July 2023.
- 2Of 691 devices analyzed, 531 targeted radiology applications.
- 3Fewer than 30% of devices provided data on safety, efficacy, or adverse events prior to approval.
- 4No predefined efficacy or safety reporting standards currently exist for AI/ML devices in the U.S., unlike with pharmaceuticals.
- 5The findings highlight a regulatory gap and call for stricter testing and dedicated approval pathways for AI/ML-based medical devices.
Why It Matters
This research underscores a major gap in regulatory standards and transparency for AI devices in radiology, potentially impacting patient safety and trust. Addressing these concerns could lead to more robust evidence and safer adoption of AI in clinical imaging practice.
Source
Radiology Business
Related News
•AuntMinnie
AI’s Path in Radiology Hinges on Tech, Policy, and Human Insight
SIIM-CAIMI keynote highlights that AI's future in radiology depends on synchronized advances in technology, regulation, finance, and culture.
•Radiology Business
Meta Funds Ohio State’s Radiology AI Innovation Projects
Meta will fund Ohio State researchers to explore AI-driven advancements in radiology, including chest X-ray reporting and disease prediction.
•AuntMinnie
SIIM-CAIMI Leaders Discuss Key Trends in Imaging AI Deployment
SIIM-CAIMI program chairs highlight AI's transition from algorithm evaluation to real-world implementation in medical imaging.